BRAF and colorectal cancer: Therefore, both the three-drug combination (encorafenib, binimetinib, and cetuximab) for BRAF V600E mutation-positive colorectal cancer and the two-drug combination (encorafenib and cetuximab) are considered standard treatment options for BRAF V600E mutation-positive colorectal cancer.